LIVZON PHARMA (01513.HK): Proposes Appointment of Zhu Linlin as Non-Executive Director of the Twelfth Board

NewTimeSpace News: On 18 September 2026, Livzon Pharmaceutical Group Inc. (stock code: 01513) announced that, following approval by the nomination committee of the Board, the Board has approved the nomination of Zhu Linlin as a candidate for non-executive director of the twelfth session of the Board, for a term from the date of approval by the Company's extraordinary general meeting until the expiry of the term of the twelfth session of the Board. The proposed appointment is subject to approval by ordinary resolution at the extraordinary general meeting.

If the appointment becomes effective, the Company will enter into a director's service contract with Zhu Linlin, who will receive an annual director's fee of RMB 96,000 (before tax) as a non-executive director. Zhu Linlin, aged 31, holds a Master's degree in Applied Economics from Johns Hopkins University and has extensive experience in marketing, business development and corporate management in the pharmaceutical and healthcare industry. She served as general manager and vice chairwoman of Maohaizi Animal Health (Guangdong) Co., Ltd. from April 2023 to February 2026 and has been its chairwoman since March 2026. Zhu Linlin is the daughter of Zhu Baoguo, the ultimate controller of the Company, and currently serves as a director of PT Livzon Pharma Indonesia, an overseas subsidiary of the Company.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.